These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Evaluating the costs of glycemic response with canagliflozin versus dapagliflozin and empagliflozin as add-on to metformin in patients with type 2 diabetes mellitus in the United Arab Emirates. Schubert A; Buchholt AT; El Khoury AC; Kamal A; Taieb V Curr Med Res Opin; 2017 Jun; 33(6):1155-1163. PubMed ID: 28323512 [TBL] [Abstract][Full Text] [Related]
25. Dapagliflozin therapy in type-2 diabetes: current knowledge and future perspectives. Rizzo M; Al-Busaidi N; Rizvi AA Expert Opin Pharmacother; 2015 Feb; 16(3):281-4. PubMed ID: 25516459 [TBL] [Abstract][Full Text] [Related]
26. Comparison of the pharmacokinetics and pharmacodynamics of dapagliflozin in patients with type 1 versus type 2 diabetes mellitus. Tang W; Leil TA; Johnsson E; Boulton DW; LaCreta F Diabetes Obes Metab; 2016 Mar; 18(3):236-40. PubMed ID: 26510924 [TBL] [Abstract][Full Text] [Related]
27. Dapagliflozin: more than just another oral glucose-lowering agent? Katsiki N; Papanas N; Mikhailidis DP Expert Opin Investig Drugs; 2010 Dec; 19(12):1581-9. PubMed ID: 21105857 [TBL] [Abstract][Full Text] [Related]
28. Dapagliflozin for the treatment of type 2 diabetes. Brooks AM; Thacker SM Ann Pharmacother; 2009 Jul; 43(7):1286-93. PubMed ID: 19584379 [TBL] [Abstract][Full Text] [Related]
29. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Scheen AJ Drugs; 2015 Jan; 75(1):33-59. PubMed ID: 25488697 [TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus. Kasichayanula S; Chang M; Hasegawa M; Liu X; Yamahira N; LaCreta FP; Imai Y; Boulton DW Diabetes Obes Metab; 2011 Apr; 13(4):357-65. PubMed ID: 21226818 [TBL] [Abstract][Full Text] [Related]
31. Dapagliflozin, an SGLT2 inhibitor for the treatment of type 2 diabetes. Demaris KM; White JR Drugs Today (Barc); 2013 May; 49(5):289-301. PubMed ID: 23724409 [TBL] [Abstract][Full Text] [Related]
32. Effects of dapagliflozin on cardiovascular risk factors. Ptaszynska A; Hardy E; Johnsson E; Parikh S; List J Postgrad Med; 2013 May; 125(3):181-9. PubMed ID: 23748519 [TBL] [Abstract][Full Text] [Related]
33. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Lambers Heerspink HJ; de Zeeuw D; Wie L; Leslie B; List J Diabetes Obes Metab; 2013 Sep; 15(9):853-62. PubMed ID: 23668478 [TBL] [Abstract][Full Text] [Related]
34. [Dapagliflozin. Lowering blood glucose levels by increasing glucosuria]. Hinneburg I Med Monatsschr Pharm; 2013 Apr; 36(4):128-32. PubMed ID: 23654152 [TBL] [Abstract][Full Text] [Related]
35. Saxagliptin/Dapagliflozin: A Review in Type 2 Diabetes Mellitus. Garnock-Jones KP Drugs; 2017 Mar; 77(3):319-330. PubMed ID: 28176222 [TBL] [Abstract][Full Text] [Related]
36. Effect of dapagliflozin on obstructive sleep apnea in patients with type 2 diabetes: a preliminary study. Tang Y; Sun Q; Bai XY; Zhou YF; Zhou QL; Zhang M Nutr Diabetes; 2019 Nov; 9(1):32. PubMed ID: 31685792 [TBL] [Abstract][Full Text] [Related]
37. Dapagliflozin, an oral sodium glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitus. Calado J IDrugs; 2009 Dec; 12(12):785-98. PubMed ID: 19943222 [TBL] [Abstract][Full Text] [Related]
38. Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes. DeFronzo RA; Hompesch M; Kasichayanula S; Liu X; Hong Y; Pfister M; Morrow LA; Leslie BR; Boulton DW; Ching A; LaCreta FP; Griffen SC Diabetes Care; 2013 Oct; 36(10):3169-76. PubMed ID: 23735727 [TBL] [Abstract][Full Text] [Related]
39. The kidney and type 2 diabetes mellitus: therapeutic implications of SGLT2 inhibitors. Weir MR Postgrad Med; 2016; 128(3):290-8. PubMed ID: 26821720 [TBL] [Abstract][Full Text] [Related]
40. Efficacy and Safety of Remogliflozin Etabonate, a New Sodium Glucose Co-Transporter-2 Inhibitor, in Patients with Type 2 Diabetes Mellitus: A 24-Week, Randomized, Double-Blind, Active-Controlled Trial. Dharmalingam M; Aravind SR; Thacker H; Paramesh S; Mohan B; Chawla M; Asirvatham A; Goyal R; Shembalkar J; Balamurugan R; Kadam P; Alva H; Kodgule R; Tandon M; Vaidyanathan S; Pendse A; Gaikwad R; Katare S; Suryawanshi S; Barkate H Drugs; 2020 Apr; 80(6):587-600. PubMed ID: 32162274 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]